Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: ##STR00001##
The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: ##STR00001##
The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac. ##STR00001##

The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac. ##STR00001##

Provided are methods of preparing compounds and pharmaceutical compositions comprising a compound Formula VIII for treating Filoviridae virus infections. In one aspect, the compound of Formula VIII is formed from a reaction mixture comprising the compound of Formula IX, the compound of Formula X, a coupling agent such as magnesium chloride and a non-nucleophilic base such as diisopropylethylamine. The compound of Formula IX can be formed from a compound of Formula V and a cyanating agent. The compound of Formula V can be synthesized from a reaction mixture comprising a deprotonating agent such as phenylmagnesium chloride; a silylating agent such as chlorotrimethylsilane; a coupling agent such as isopropylmagnesium chloride, an additive such as LaCl.sub.3-2LiCl, LaCl.sub.3, CeCl.sub.3, NdCl.sub.3, or YCl.sub.3; a compound of Formula VI; and 7-iodopyrrolo[2,1-f][1,2,4]triazin-4-amine. The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Provided are methods of preparing compounds and pharmaceutical compositions comprising a compound Formula VIII for treating Filoviridae virus infections. In one aspect, the compound of Formula VIII is formed from a reaction mixture comprising the compound of Formula IX, the compound of Formula X, a coupling agent such as magnesium chloride and a non-nucleophilic base such as diisopropylethylamine. The compound of Formula IX can be formed from a compound of Formula V and a cyanating agent. The compound of Formula V can be synthesized from a reaction mixture comprising a deprotonating agent such as phenylmagnesium chloride; a silylating agent such as chlorotrimethylsilane; a coupling agent such as isopropylmagnesium chloride, an additive such as LaCl.sub.3-2LiCl, LaCl.sub.3, CeCl.sub.3, NdCl.sub.3, or YCl.sub.3; a compound of Formula VI; and 7-iodopyrrolo[2,1-f][1,2,4]triazin-4-amine. The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

This application relates to efficient methods for the synthesis of ascarylose and its derivatives. A method for the production of ascarylose includes: providing, as a feedstock, a 1-O-substituted rhamnose; forming a mono-sulfonate ester at the 3—OH group of the 1-O-substituted rhamnose; and treating the mono-sulfonate ester with a hydride source to form a 1-O-substituted ascarylose. Forming the mono-sulfonate ester can advantageously be conducted on a 1-O-substituted rhamnose without hydroxyl protecting groups at either the 2—OH or 4—OH—positions.

The present invention relates to a high anticoagulation activity compound, a preparation method and an application, said compound being formed from a monosaccharide unit D, a monosaccharide unit E, a 6-position carbon oxygen-substituted monosaccharide unit F, a monosaccharide unit G and a monosaccharide unit H sequentially connected by glycosidic bonds, the bond three-dimensional configuration being a-D-glucose-(1.fwdarw.4)-0-p-D-glucuronic acid-(1.fwdarw.4)-0-a-D-(6-carbon oxygen-substituted)glucose-(1.fwdarw.4)-0-a-L-iduronic acid-(1-4)-0-a-D-(6-carbon oxygen-substituted)methyl glucose. The monosaccharide unit D is a glucose 2,6-O-sulfated group, the monosaccharide unit E is a glucuronidated group, the monosaccharide unit F is a glucose 2,3-0-6-carbon oxygen-substituted-sulfated group, the monosaccharide unit G is an L-iduronic acid 2-O-sulfated group, and the monosaccharide unit H is a glucose 2,3-0-6-carbon oxygen-substituted-sulfated group. The synthesized compound has higher anticoagulation activity than when the 6-positions of the F unit and H unit are oxygen.

The present invention relates to a high anticoagulation activity compound, a preparation method and an application, said compound being formed from a monosaccharide unit D, a monosaccharide unit E, a 6-position carbon oxygen-substituted monosaccharide unit F, a monosaccharide unit G and a monosaccharide unit H sequentially connected by glycosidic bonds, the bond three-dimensional configuration being a-D-glucose-(1.fwdarw.4)-0-p-D-glucuronic acid-(1.fwdarw.4)-0-a-D-(6-carbon oxygen-substituted)glucose-(1.fwdarw.4)-0-a-L-iduronic acid-(1-4)-0-a-D-(6-carbon oxygen-substituted)methyl glucose. The monosaccharide unit D is a glucose 2,6-O-sulfated group, the monosaccharide unit E is a glucuronidated group, the monosaccharide unit F is a glucose 2,3-0-6-carbon oxygen-substituted-sulfated group, the monosaccharide unit G is an L-iduronic acid 2-O-sulfated group, and the monosaccharide unit H is a glucose 2,3-0-6-carbon oxygen-substituted-sulfated group. The synthesized compound has higher anticoagulation activity than when the 6-positions of the F unit and H unit are oxygen.